Last reviewed · How we verify
Transient Continuous Subcutaneous Insulin Infusion
Transient continuous subcutaneous insulin infusion delivers insulin intermittently via subcutaneous infusion to improve glycemic control in diabetes.
Transient continuous subcutaneous insulin infusion delivers insulin intermittently via subcutaneous infusion to improve glycemic control in diabetes. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus requiring insulin therapy.
At a glance
| Generic name | Transient Continuous Subcutaneous Insulin Infusion |
|---|---|
| Also known as | CSII |
| Sponsor | Shanghai Jiao Tong University School of Medicine |
| Drug class | Insulin delivery system |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a delivery system technology rather than a novel molecular entity. It administers insulin through periodic subcutaneous infusions, designed to mimic physiological insulin secretion patterns more closely than conventional insulin injection regimens. The transient nature suggests intermittent rather than continuous delivery, potentially reducing hypoglycemia risk while maintaining glycemic control.
Approved indications
- Type 1 diabetes mellitus
- Type 2 diabetes mellitus requiring insulin therapy
Common side effects
- Hypoglycemia
- Injection site reactions
- Hyperglycemia
- Infusion set occlusion
Key clinical trials
- Closed-loop Control of Postprandial Glucose Levels in Children and Adults With Type 1 Diabetes (PHASE2)
- Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy (PHASE4)
- Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: